Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3772847 in Moderately Severe Asthma
NCT03207243Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2017
- Primary completion
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of melrilimab in asthma, sponsored by GSK. Started Sep 2017; status: completed.
02
Drugs
melrilimab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03207243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03207243.